The BIEL + Viant Medical + VLMS Healthcare Wealth Engine
A Connected Pain Platform with Open-Market Equity, Global Scale, and Netflix-Level Growth Potential
Vision: Pain Relief That Powers Prosperity
BioElectronics Corporation (BIEL) is revolutionizing pain therapy and wellness with its FDA-cleared PEMF devices—ActiPatch®, RecoveryRx®, and RecoveryRx Veterinary®. Backed by Viant Medical’s manufacturing scale and VLMS Healthcare’s digital precision, BIEL blends AI-driven therapy, lean infrastructure, and open-market equity ownership into a platform built for breakout growth.
This isn’t a startup—it’s a 20-year foundation. No permission needed to join—just own a share (or a billion).
EASY $$$ Model
✅ No bureaucracy (regulations, lawyers and associated high costs)
✅ No restructuring
✅ No joint ventures
Instead, retail chains, hospital systems, payers, and distributors can acquire shares directly, participate in expansion, and benefit from PPS appreciation.
Performance becomes investment. Ownership becomes reward.
Netflix Economics—But Better
Similar price point (~$35 for 720 hours/1 month of therapy)
No studios, no celebrities—just high-impact tech
Serves both humans and animals
No new FDA approvals needed for wellness applications
Higher margins. Lower overhead. Global market access.
Execution at Global Scale
ActiPatch is gaining worldwide traction, with Viant and VLMS powering expansion:
Taiwan: 14 hospitals → clinical validation + reimbursement
South Africa: Nationwide retail/e-commerce rollout via Adcock Ingram
New Zealand: Direct-to-consumer launch → payer pathways + logistics activated
Every new territory increases valuation and amplifies partner equity.
Veterinary Goldmine
RecoveryRx Veterinary® quietly disrupts a premium market:
Competes with Assisi Loop ($329 with 1/20 the battery life)
Repeat buyers spend $6K/year for lower-value products
Outperforms on price, value, and lifecycle
E-commerce + wellness bundling = next major growth vertical
Wellness Explosion: Untapped Cash Flow
Off-label use fuels direct retail growth:
Migraines
Menstrual pain
Diabetic neuropathy
Restless Leg Syndrome (affects 10% globally)
Opioid reduction
BPH + bladder dysfunction via vagus stimulation
These segments require no new FDA clearance, creating fast-lane opportunities for influencers and wellness brands.
Milestones That Matter
Strategic execution triggers PPS acceleration:
1️⃣ $0.0004–0.0005: Technical breakout + media buzz
2️⃣ $0.003: 3,000% surge = outperforming Apple, Amazon, Microsoft...
3️⃣ $0.01: $400K quarter → copper
4️⃣ $0.04: $10M profit → parallels Bitcoin’s historic run
5️⃣ $0.10–$1: Share buybacks, viral demand, and legacy-level investor returns
Squeeze inevitable with ~10B float and ~15B long-term holders.
ROI in Action
VLMS turns backend billing into real-time equity appreciation
Viant powers deployment, ensuring scalable valuation
Partners grow with no carve-outs, dilution, or bureaucratic delay
Governance participation via voting + board seats
Full autonomy, liquidity, and upside
✅ This is equity in motion.
AI: The Smart Engine Beneath Smart Relief
Artificial intelligence fuels performance across every layer:
Personalized Targeting: AI identifies pain-specific consumer subgroups for high-conversion marketing
Predictive Forecasting: Viant scales manufacturing based on region-specific AI demand insights
Retention & Engagement: VLMS deploys AI chatbots, sentiment analysis, and churn prediction for LTV lift
Financial Precision: AI models cash flow, billing trends, and PPS targets in real time
Bottom Line: AI reduces CAC, boosts retention, and automates scale—each product shipped sharpens PPS growth.
PPS Advantage: High-Impact Equity Access for Partners
BIEL’s ultra-low PPS is a game-changing strategic asset:
Fast Entry: Viant, VLMS, and others can purchase shares instantly—no contracts, no red tape
Lowest Possible Cost Basis: Partners accumulate equity at early-stage valuations with exponential upside
No Bureaucracy, No Dilution: Clean participation without complex cap tables or negotiation delays
Real-Time Value: Every sale, rollout, or reimbursement win immediately increases the value of partner-held equity
No paperwork. No waiting. Just performance-to-profit simplicity.
Final Word: Built to Breakout
Viant builds. VLMS bills. BIEL heals. And shareholders prosper.
With policy momentum, wellness virality, veterinary demand, AI optimization, and open equity mechanics—the BIEL + Viant Medical + VLMS Healthcare is one of the most scalable, accessible, and high-performance wealth engines in healthcare.
This isn’t hype. It’s execution. Join the mission. Own the upside. Profit from pain relief.
A Connected Pain Platform with Open-Market Equity, Global Scale, and Netflix-Level Growth Potential
Vision: Pain Relief That Powers Prosperity
BioElectronics Corporation (BIEL) is revolutionizing pain therapy and wellness with its FDA-cleared PEMF devices—ActiPatch®, RecoveryRx®, and RecoveryRx Veterinary®. Backed by Viant Medical’s manufacturing scale and VLMS Healthcare’s digital precision, BIEL blends AI-driven therapy, lean infrastructure, and open-market equity ownership into a platform built for breakout growth.
This isn’t a startup—it’s a 20-year foundation. No permission needed to join—just own a share (or a billion).
EASY $$$ Model
✅ No bureaucracy (regulations, lawyers and associated high costs)
✅ No restructuring
✅ No joint ventures
Instead, retail chains, hospital systems, payers, and distributors can acquire shares directly, participate in expansion, and benefit from PPS appreciation.
Performance becomes investment. Ownership becomes reward.
Netflix Economics—But Better
Similar price point (~$35 for 720 hours/1 month of therapy)
No studios, no celebrities—just high-impact tech
Serves both humans and animals
No new FDA approvals needed for wellness applications
Higher margins. Lower overhead. Global market access.
Execution at Global Scale
ActiPatch is gaining worldwide traction, with Viant and VLMS powering expansion:
Taiwan: 14 hospitals → clinical validation + reimbursement
South Africa: Nationwide retail/e-commerce rollout via Adcock Ingram
New Zealand: Direct-to-consumer launch → payer pathways + logistics activated
Every new territory increases valuation and amplifies partner equity.
Veterinary Goldmine
RecoveryRx Veterinary® quietly disrupts a premium market:
Competes with Assisi Loop ($329 with 1/20 the battery life)
Repeat buyers spend $6K/year for lower-value products
Outperforms on price, value, and lifecycle
E-commerce + wellness bundling = next major growth vertical
Wellness Explosion: Untapped Cash Flow
Off-label use fuels direct retail growth:
Migraines
Menstrual pain
Diabetic neuropathy
Restless Leg Syndrome (affects 10% globally)
Opioid reduction
BPH + bladder dysfunction via vagus stimulation
These segments require no new FDA clearance, creating fast-lane opportunities for influencers and wellness brands.
Milestones That Matter
Strategic execution triggers PPS acceleration:
1️⃣ $0.0004–0.0005: Technical breakout + media buzz
2️⃣ $0.003: 3,000% surge = outperforming Apple, Amazon, Microsoft...
3️⃣ $0.01: $400K quarter → copper
4️⃣ $0.04: $10M profit → parallels Bitcoin’s historic run
5️⃣ $0.10–$1: Share buybacks, viral demand, and legacy-level investor returns
Squeeze inevitable with ~10B float and ~15B long-term holders.
ROI in Action
VLMS turns backend billing into real-time equity appreciation
Viant powers deployment, ensuring scalable valuation
Partners grow with no carve-outs, dilution, or bureaucratic delay
Governance participation via voting + board seats
Full autonomy, liquidity, and upside
✅ This is equity in motion.
AI: The Smart Engine Beneath Smart Relief
Artificial intelligence fuels performance across every layer:
Personalized Targeting: AI identifies pain-specific consumer subgroups for high-conversion marketing
Predictive Forecasting: Viant scales manufacturing based on region-specific AI demand insights
Retention & Engagement: VLMS deploys AI chatbots, sentiment analysis, and churn prediction for LTV lift
Financial Precision: AI models cash flow, billing trends, and PPS targets in real time
Bottom Line: AI reduces CAC, boosts retention, and automates scale—each product shipped sharpens PPS growth.
PPS Advantage: High-Impact Equity Access for Partners
BIEL’s ultra-low PPS is a game-changing strategic asset:
Fast Entry: Viant, VLMS, and others can purchase shares instantly—no contracts, no red tape
Lowest Possible Cost Basis: Partners accumulate equity at early-stage valuations with exponential upside
No Bureaucracy, No Dilution: Clean participation without complex cap tables or negotiation delays
Real-Time Value: Every sale, rollout, or reimbursement win immediately increases the value of partner-held equity
No paperwork. No waiting. Just performance-to-profit simplicity.
Final Word: Built to Breakout
Viant builds. VLMS bills. BIEL heals. And shareholders prosper.
With policy momentum, wellness virality, veterinary demand, AI optimization, and open equity mechanics—the BIEL + Viant Medical + VLMS Healthcare is one of the most scalable, accessible, and high-performance wealth engines in healthcare.
This isn’t hype. It’s execution. Join the mission. Own the upside. Profit from pain relief.
1
